Stockscreener 앱 받기
104.83
0.02%
-0.02
시장 영업 전:
104.82
-0.01
-0.01%
전일 마감가:
$104.85
열려 있는:
$104.85
하루 거래량:
10.87M
Relative Volume:
4.07
시가총액:
$7.39B
수익:
-
순이익/손실:
$-153.72M
주가수익비율:
-52.41
EPS:
-2
순현금흐름:
$-103.81M
1주 성능:
+14.53%
1개월 성능:
+16.41%
6개월 성능:
+131.92%
1년 성능:
+394.02%
1일 변동 폭
$104.79
$104.93
1주일 범위
$86.63
$104.99
52주 변동 폭
$18.51
$104.99
Verona Pharma Plc Adr Stock (VRNA) Company Profile
명칭
Verona Pharma Plc Adr
전화
011-44-0-2032834200
주소
3 MORE LONDON RIVERSIDE, LONDON
VRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
104.83 | 7.39B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | TD Cowen | Buy |
| 2025-04-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2024-10-03 | 개시 | Wells Fargo | Overweight |
| 2023-05-22 | 재개 | Jefferies | Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-26 | 개시 | Piper Sandler | Overweight |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Jefferies | Buy |
| 2020-08-10 | 개시 | Canaccord Genuity | Buy |
| 2019-04-18 | 개시 | BTIG Research | Buy |
모두보기
Verona Pharma Plc Adr 주식(VRNA)의 최신 뉴스
American pharmaceutical company Merck acquires British Verona Pharma for $10 billion - AKM.RU
Verona Pharma stock hits all-time high at 104.83 USD - Investing.com
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck to acquire Verona Pharma for $10 billion - Investing.com Australia
Merck to acquire Verona Pharma for $10 billion By Investing.com - Investing.com South Africa
Can Verona Pharma Plc ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Best Momentum Stock To Buy For July 7th - Barchart.com
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data - Benzinga
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Verona Pharma stock soars to all-time high of $74.36 By Investing.com - Investing.com UK
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
TD Cowen starts Verona Pharma stock at Buy, sets $100 target - Investing.com
Verona Pharma Shareholders Approve All Proposals at AGM By Investing.com - Investing.com South Africa
Verona Pharma Shareholders Approve All Proposals at AGM - Investing.com
A significant driver of top-line growth: Verona Pharma Plc ADR (VRNA) - Sete News
Is Astrazeneca plc ADR (AZN) positioned for future growth? - Sete News
Verona Pharma Plc ADR [VRNA] Records 50-Day SMA of $62.73 - knoxdaily.com
Tencent Music Entertainment Group ADR [TME] Officer makes an insider purchase of 1,036,363 shares worth 14.87 million. – Knox Daily - knoxdaily.com
TAL Education Group ADR [TAL] Officer makes an insider purchase of 24,041 shares worth 0.28 million. - knoxdaily.com
Ratios Uncovered: Breaking Down Verona Pharma Plc ADR (VRNA)’s Trailing Twelve Months Metrics - DWinneX
Verona Pharma Plc ADR (VRNA) is a good investment, but the stock may be overvalued - uspostnews.com
What is the investor’s view on Marriott Vacations Worldwide Corp (VAC)? - uspostnews.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Financial Health Report: Alamos Gold Inc (AGI)’s Ratios Tell a Tale - DWinneX
Cantor Fitzgerald sets $80 target on Verona Pharma stock By Investing.com - Investing.com South Africa
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit undervalued - uspostnews.com
Verona Pharma Plc ADR [VRNA] Rickard Kathleen A. sells 79,264 Shares for $0.66 million - knoxdaily.com
Verona Pharma Plc ADR [VRNA] Chief Medical Officer makes an insider purchase of 79,264 shares worth 0.66 million. - knoxdaily.com
Verona Pharma secures $450 million credit facility on better terms By Investing.com - Investing.com South Africa
Verona Pharma secures $450 million credit facility on better terms - Investing.com
Xeris Biopharma reshuffles board, appoints new director - Investing.com
The growth track for Cracker Barrel Old Country Store Inc (CBRL) has changed recently - SETE News
Verona Pharma Plc Adr (VRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verona Pharma Plc Adr 주식 (VRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rickard Kathleen A. | Chief Medical Officer |
Jul 07 '25 |
Option Exercise |
0.00 |
86,064 |
0 |
2,632,536 |
| Fisher Andrew | General Counsel |
Jul 07 '25 |
Option Exercise |
0.00 |
86,064 |
0 |
446,063 |
| ZACCARDELLI DAVID | President and CEO |
Jul 07 '25 |
Option Exercise |
0.00 |
229,512 |
0 |
13,419,680 |
| Fisher Andrew | General Counsel |
Jun 16 '25 |
Option Exercise |
2.01 |
80,000 |
160,904 |
439,999 |
| Fisher Andrew | General Counsel |
Jun 16 '25 |
Sale |
11.53 |
80,000 |
922,000 |
359,999 |
| Hahn Mark W | Chief Financial Officer |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,360 |
12,278,992 |
| ZACCARDELLI DAVID | President and CEO |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,520 |
13,190,168 |
2.10%
1.57%
자본화:
|
볼륨(24시간):